Actinogen Medical (ASX:ACW)
ASX announcement history & article coverage
Transparent by design.
Announcments by Actinogen Medical (ASX:ACW) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Notification of buy-back - ACW
AGM date and closing date for director nominations
Application for quotation of securities - ACW
Options underwriting cleansing notice
Application for quotation of securities - ACW
Underwriting of unlisted options completed
Actinogen Medical completes options underwriting, securing $4.77 million and extending cash runway
ACW Alzheimers pivotal trial completes last patient visit
Actinogen completes final XanaMIA patient visit, with Alzheimer’s trial results due in November
Notification of cessation of securities - ACW
Application for quotation of securities - ACW
Application for quotation of securities - ACW
Appendix 3Y-Dr Geoffrey Brooke
Application for quotation of securities - ACW
ACW CMO international Xanamem presentation
Application for quotation of securities - ACW
Application for quotation of securities - ACW
Response to ASX Price Query
Actinogen Medical confirms no undisclosed information amid unusual trading; updates on clinical trials and compliance
Application for quotation of securities - ACW
Proposed issue of securities - ACW
ACW unlisted options fully underwritten
Actinogen Medical secures $4.77 million through full underwriting of unlisted options ahead of pivotal Alzheimer’s trial results
Application for quotation of securities - ACW
Appendix 3Y-Dr George Morstyn
Appendix 3Y-Dr Geoffrey Brooke
Application for quotation of securities - ACW
Appendix 4G
Corporate Governance Statement
ACW FY2026 results and outlook
Actinogen Medical FY2026 results highlight imminent Alzheimer's trial data and regulatory progress
ACW Appendix 4E and 2026 annual report
Actinogen Medical reports FY2026 loss, advances Alzheimer's drug Xanamem with pivotal trial results due November
Appendix 3Y - Dr George Morstyn
Application for quotation of securities - ACW
Appendix 3Y-Malcolm McComas
Application for quotation of securities - ACW
ACW webinar today, The future of Alzheimers treatment
Updated Securities Trading Policy
Application for quotation of securities - ACW
Notification of cessation of securities - ACW
ACW Bioshares presentation, strong cortisol rationale
Application for quotation of securities - ACW
ACW webinar on the future of Alzheimers treatment
June 2026 Quarterly activity report & Appendix 4C
Actinogen advances Alzheimer's trial with positive regulatory feedback and strong cash position
Application for quotation of securities - ACW
Application for quotation of securities - ACW
Xanamem depression trial published in British J Psychiatry
Actinogen Medical publishes positive phase 2 trial results for Xanamem in depression
